← Explorer/Network

Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins

Huizinga TW, Amos CI, van der Helm-van Mil AH +12 more2005Arthritis & RheumatismJournal Article
10.1002/art.21385PubMed
Immune/InnateMusculoskeletal

Abstract

AbstractObjectiveThe main genetic risk factor for rheumatoid arthritis (RA), the HLA region, has been known for 25 years. Previous research has demonstrated, within the RA population, an association between HLA–DRB1 alleles carrying the shared epitope (SE) and antibodies directed against cyclic citrullinated peptides (anti‐CCP antibodies). We undertook this study to make the first comparison of SE allele frequencies in the healthy population with those in RA patients who do or do not harbor anti‐CCP antibodies.MethodsHLA–DRB1 typing was performed in 408 RA patients from the Leiden Early Arthritis Clinic (the Leiden EAC; a Dutch population‐based inception cohort in which disease course was followed up over time), in 423 healthy Dutch controls, and in 720 affected members of 341 US multiplex (sibpair) families of Caucasian origin from the North American RA Consortium (NARAC) with well‐established disease and fulfilling the American College of Rheumatology classification criteria for RA. The presence of anti‐CCP antibodies was determined by enzyme‐linked immunosorbent assay.ResultsFor the Leiden EAC, the odds ratio (OR) describing the association of 2 copies of the SE allele with anti‐CCP positivity (using no copies of the SE allele in the healthy control group as the referent) was 11.79 (P < 0.0001), while the OR for 1 SE allele was 4.37 (P < 0.0001). No association with the SE was observed in the Dutch anti‐CCP–negative RA patients. For the NARAC families, linkage and association analysis revealed the SE to be associated only with anti‐CCP–positive disease and not with anti‐CCP–negative disease. Stratified analyses indicated that anti‐CCP antibodies primarily mediated association of the SE with joint damage or disease persistence.ConclusionHLA–DRB1 alleles encoding the SE are specific for disease characterized by antibodies to citrullinated peptides, indicating that these alleles do not associate with RA as such, but rather with a particular phenotype.

Key Biomarkers

anti-CCP antibodiescitrullinated peptidesHLA-DRB1 shared epitope

Symptom Clusters

disease persistencejoint damage

Cited By (4)

  • The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritisArthritis & Rheumatism · 2006
  • Contribution of Fcγ receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritisAnnals of the Rheumatic Diseases · 2008
  • Redefining the HLA and RA association: to be or not to be anti-CCP positiveJournal of Autoimmunity · 2005
  • Differential association of HLA-DRB1 alleles in Japanese patient with early rheumatoid arthritis in relationship to autoantibodies to cyclic citrullinated peptidePubMed · 2007

References (2)

  • Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritisArthritis & Rheumatism · 2004
  • Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis

Related Papers

  • Pro-resolving and anti-arthritic properties of the MC1 selective agonist PL8177Frontiers in Immunology · 2022 · 2 shared tags
  • A Transcriptomic Fingerprint for Parkinson's Disease Found in Patients with Chronic Inflammatory Response Syndrome: Implications for Diagnosis, Treatment and PreventionMedical Research Archives · 2024 · 2 shared tags
  • Inflammation and osteosarcopeniaElsevier eBooks · 2022 · 2 shared tags
  • A Narrative Review of the Immunomodulatory Effects of Acthar® Gel Beyond Its Steroidogenic PropertiesAdvances in Therapy · 2025 · 2 shared tags
  • Phytoplankton Toxins and Their Potential Therapeutic Applications: A Journey toward the Quest for Potent PharmaceuticalsMarine Drugs · 2022 · 2 shared tags
  • Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administrationImmunotherapy Advances · 2023 · 2 shared tags
Arthritis & Rheumatism · 2005